The Company and Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2015

Accounting Policies [Abstract]

Basic and Diluted Net Income per Ordinary Share Computation

Basic and diluted net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share were computed as follows (in thousands, except per share amounts):

	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
Numerator:
Net income (loss) attributable to Jazz Pharmaceuticals plc	$	88,114	$	43,659	$	158,814	$	(48,991	)
Denominator:
Weighted-average ordinary shares used in calculating net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share - basic	61,190		59,519		60,998		59,025
Dilutive effect of employee equity incentive and purchase plans	1,900		2,293		2,030		—
Dilutive effect of warrants	—		566		—		—
Weighted-average ordinary shares used in calculating net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share - diluted	63,090		62,378		63,028		59,025
Net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share:
Basic	$	1.44	$	0.73	$	2.60	$	(0.83	)
Diluted	$	1.40	$	0.70	$	2.52	$	(0.83	)

Weighted-Average Ordinary Shares Excluded from Computation of Diluted Net Income per Share

The following table represents the weighted-average ordinary shares that were excluded from the computation of diluted net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share for the periods presented because including them would have an anti-dilutive effect (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,
	2015	2014	2015	2014
1.875% exchangeable senior notes due 2021	2,878	—	2,878	—
Options to purchase ordinary shares and RSUs	1,586	1,088	1,453	5,526
Warrants to purchase ordinary shares	—	—	—	928
Ordinary shares under ESPP	—	—	—	137